trial · primary record
Azacitidine
Recurrent Anaplastic Large Cell Lymphoma
| Phase | Phase 1 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 40 |
| Primary completion | 2029-11-24 |
| Primary endpoint | Occurrence of dose-limiting toxicities (DLT) (Arm A) |
| Registry ID | NCT07691450 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:43:27.352Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07691450
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.
Same entity, elsewhere in the suite
- Azacitidine · approval
- Azacitidine · compound